Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.48 and traded as low as $2.25. Oramed Pharmaceuticals shares last traded at $2.34, with a volume of 44,022 shares traded.
Oramed Pharmaceuticals Stock Performance
The company's 50 day simple moving average is $2.78 and its 200 day simple moving average is $2.48. The stock has a market cap of $94.82 million, a PE ratio of 16.71 and a beta of 1.87.
Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last released its earnings results on Wednesday, March 6th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.04. Equities research analysts expect that Oramed Pharmaceuticals Inc. will post -0.26 earnings per share for the current year.
Hedge Funds Weigh In On Oramed Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in ORMP. BML Capital Management LLC grew its holdings in Oramed Pharmaceuticals by 61.5% during the fourth quarter. BML Capital Management LLC now owns 1,261,559 shares of the biotechnology company's stock valued at $2,914,000 after purchasing an additional 480,267 shares during the period. Rathbones Group PLC bought a new position in shares of Oramed Pharmaceuticals in the third quarter worth $756,000. Assenagon Asset Management S.A. purchased a new position in Oramed Pharmaceuticals during the 1st quarter valued at about $54,000. Algert Global LLC bought a new stake in shares of Oramed Pharmaceuticals during the third quarter valued at about $38,000. Finally, N.E.W. Advisory Services LLC bought a new stake in Oramed Pharmaceuticals during the 3rd quarter worth approximately $34,000. Institutional investors own 12.73% of the company's stock.
About Oramed Pharmaceuticals
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Featured Stories
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
